Health Care·Biotechnology·$20.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.37 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.37 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a positive outlook on their long-term strategy despite the current EPS miss. They emphasized their commitment to innovation and growth.
Management expressed excitement about ongoing research and development efforts.
They highlighted the importance of their pipeline in addressing future health needs.
Despite reporting a loss in EPS, Moderna's stock surged by 22.73% following the earnings report. This increase suggests that investors are optimistic about the company's future potential, particularly in its research and development pipeline. The management's positive tone likely contributed to this strong stock performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ONEOK INC NEW
Feb 24, 2020